Abstract
Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.
Keywords: Fibroblast, myofibroblast, myocardial infarction, heart, cardiac remodeling, heart failure.
Current Pharmaceutical Design
Title:Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Volume: 20 Issue: 12
Author(s): Evangelos P. Daskalopoulos, Kevin C.M. Hermans and W. Matthijs Blankesteijn
Affiliation:
Keywords: Fibroblast, myofibroblast, myocardial infarction, heart, cardiac remodeling, heart failure.
Abstract: Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.
Export Options
About this article
Cite this article as:
Daskalopoulos P. Evangelos, Hermans C.M. Kevin and Blankesteijn Matthijs W., Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction, Current Pharmaceutical Design 2014; 20 (12) . https://dx.doi.org/10.2174/13816128113199990452
DOI https://dx.doi.org/10.2174/13816128113199990452 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Garlic and its Active Compounds: A Potential Candidate in The Prevention of Cancer by Modulating Various Cell Signalling Pathways
Anti-Cancer Agents in Medicinal Chemistry Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Microvascular Alterations in Hypertension and Vascular Aging
Current Hypertension Reviews Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytostatic Effect of the Nucleoside Analogue 2-Chloroadenosine on Human Prostate Cancer Cell Line
Current Pharmaceutical Analysis Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases
Current Molecular Medicine Oxidative Stress in Polycystic Ovary Syndrome
Current Pharmaceutical Design Relation Between Obstructive Sleep Apnea Syndrome and Resistant Hypertension - The Tip of the Iceberg
Current Respiratory Medicine Reviews Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design